Compare BFC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | ZYME |
|---|---|---|
| Founded | 1894 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2018 | 2022 |
| Metric | BFC | ZYME |
|---|---|---|
| Price | $155.29 | $21.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $157.00 | $38.90 |
| AVG Volume (30 Days) | 82.1K | ★ 412.3K |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | 11.23 | ★ 33.33 |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $58.67 | $183.10 |
| Revenue Next Year | $2.01 | N/A |
| P/E Ratio | $85.81 | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $115.29 | $11.86 |
| 52 Week High | $154.42 | $29.75 |
| Indicator | BFC | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 35.87 |
| Support Level | $134.81 | $17.27 |
| Resistance Level | N/A | $23.66 |
| Average True Range (ATR) | 4.97 | 0.83 |
| MACD | 0.53 | -0.24 |
| Stochastic Oscillator | 91.09 | 13.04 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.